Selumetinib in combination with dexamethasone for the treatment of relapsed/refractory RAS-pathway mutated paediatric and adult acute lymphoblastic leukaemia (SeluDex): study protocol for an international, parallel-group, dose-finding with expansion phase I/II trial

INTRODUCTION: Event-free survival rates at 15 years for paediatric patients with relapsed/refractory acute lymphoblastic leukaemia (ALL) are 30%–50%, with 5-year survival for adult patients only 20%. Many patients with newly diagnosed and relapsed ALL harbour somatic RAS-signalling activation mutati...

Descripción completa

Detalles Bibliográficos
Autores principales: Menne, Tobias, Slade, Daniel, Savage, Joshua, Johnson, Sarah, Irving, Julie, Kearns, Pamela, Plummer, Ruth, Shenton, Geoff, Veal, Gareth J, Vormoor, Britta, Vormoor, Josef, Billingham, Lucinda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Haematology (Incl Blood Transfusion)
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8900053/
https://www.ncbi.nlm.nih.gov/pubmed/35246426
http://dx.doi.org/10.1136/bmjopen-2021-059872

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8900053/
https://www.ncbi.nlm.nih.gov/pubmed/35246426
http://dx.doi.org/10.1136/bmjopen-2021-059872

Ejemplares similares